These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 12522485

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
    Dasgupta B, King M.
    Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
    [Abstract] [Full Text] [Related]

  • 3. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
    Feng W, Garrett H, Speert DP, King M.
    Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
    [Abstract] [Full Text] [Related]

  • 4. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M, Dasgupta B, Tomkiewicz RP, Brown NE.
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [Abstract] [Full Text] [Related]

  • 5. The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis.
    Homnick DN, Marks JH, Rubin BK.
    J Aerosol Med; 2007 Jul; 20(1):45-9. PubMed ID: 17388752
    [Abstract] [Full Text] [Related]

  • 6. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME.
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [Abstract] [Full Text] [Related]

  • 7. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis.
    App EM, Baran D, Dab I, Malfroot A, Coffiner M, Vanderbist F, King M.
    Eur Respir J; 2002 Feb; 19(2):294-302. PubMed ID: 11866009
    [Abstract] [Full Text] [Related]

  • 8. Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro.
    Rubin BK, Kater AP, Goldstein AL.
    Chest; 2006 Nov; 130(5):1433-40. PubMed ID: 17099021
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of osmolality on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum.
    Shibuya Y, Wills PJ, Cole PJ.
    Respirology; 2003 Jun; 8(2):181-5. PubMed ID: 12753533
    [Abstract] [Full Text] [Related]

  • 13. Physical and transport properties of sputum from children with idiopathic bronchiectasis.
    Redding GJ, Kishioka C, Martinez P, Rubin BK.
    Chest; 2008 Dec; 134(6):1129-1134. PubMed ID: 18753467
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. An in vitro comparison of the mucoactive properties of guaifenesin, iodinated glycerol, surfactant, and albuterol.
    Rubin BK.
    Chest; 1999 Jul; 116(1):195-200. PubMed ID: 10424525
    [Abstract] [Full Text] [Related]

  • 17. Mucus properties in children with primary ciliary dyskinesia: comparison with cystic fibrosis.
    Bush A, Payne D, Pike S, Jenkins G, Henke MO, Rubin BK.
    Chest; 2006 Jan; 129(1):118-23. PubMed ID: 16424421
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.